Vertex (VRTX) Hits Record High on Non-Opioid Pain Drug Data
Vertex (VRTX) stock hits a 52-week high after announcing encouraging data from a phase II study on non-opioid pain medicine, VX-548, for treating painful diabetic peripheral neuropathy.
Vertex (VRTX) Soars 13.2%: Is Further Upside Left in the Stock?
Vertex (VRTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in ...
Why Vertex Stock Is Soaring Today
Vertex Pharmaceuticals' NaV1.8-inhibitor VX-548 measurably reduces peripheral neuropathic pain among diabetics. The drug, however, can be used to treat similar pain stemming from other health condi...
Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?
Vertex and partner CRISPR Therapeutics just won FDA approval for blood disorders treatment exa-cel -- to be commercialized as Casgevy. Vertex is known for its cystic fibrosis drugs, which bring in ...
The FDA just approved the first gene editing therapy for sickle cell anemia, but it'll cost $2.2 million per person
The FDA approved the first gene therapies for sickle cell anemia. The two approved treatments, Casgevy and Lyfgenia, will cost $2.2 million and $3.1 million.
Forget the "Magnificent Seven": Buy This Stock Instead
The "Magnificent Seven" are all great stocks to own, but none has an actual monopoly in its field. Vertex Pharmaceuticals does have a monopoly in selling certain medicines critical to patients' hea...
U.S. poised to approve first gene-editing treatment in breakthrough for sickle cell patients
The U.S. Food and Drug Administration is expected to approve exa-cel for sickle cell disease in what would become the first marketed medicine to use CRISPR.
This healthcare stock could skyrocket anytime
Vertex Pharmaceuticals (NASDAQ: VRTX) boasts an impressive track record, establishing itself as a leading biotech firm over the last decade. The company has demonstrated a keen emphasis on addressi...
Vertex (VRTX) Gets EU Nod for Kaftrio Use in 2-5 Year Kids
The European Commission approves Vertex's (VRTX) Kaftrio for expanded use to treat children aged two to five years with cystic fibrosis.
Vertex (VRTX) Non-Cystic Fibrosis Pipeline Boosts Stock This Year
Vertex Pharmaceuticals (VRTX) is likely to achieve multiple clinical milestones in late/2023 and 2024, both in its CF and non-CF portfolio.
Vertex Pharmaceuticals Incorporated (VRTX) Jefferies Global Healthcare Conference Call Transcript
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) Jefferies Global Healthcare Conference Call November 14, 2023 3:30 AM ET Company Participants Stuart Arbuckle - Executive Vice President and Chief...
Vertex Pharmaceuticals Incorporated (VRTX) Presents at UBS Biopharma Conference (Transcript)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX ) UBS Biopharma Conference November 9, 2023 12:00 PM ET Company Participants Charlie Wagner - Executive Vice President & Chief Financial Officer Dav...
Why you can make Vertex Pharmaceuticals a buy on any pullback
Shares of Vertex Pharmaceuticals, Inc. NASDAQ: VRTX are down nearly 2% after the company delivered its third-quarter earnings report. The news wasn't particularly bad, although there was a slight m...
4 Reasons to Worry About Vertex Pharmaceuticals -- Debunked
Vertex's Q3 update could have made some investors at least a little more nervous. However, there are four reasons some might be concerned that are easily debunked.
Vertex (VRTX) Q3 Earnings Beat, Sales Miss, Raises '23 View
Vertex's (VRTX) third-quarter results reflect a year-over-year increase in revenues. The company raises its net product sales guidance for 2023.
Related Companies